New Immunotherapy Drug Could Help Shrink Colon Tumors
Early results suggest this immunotherapy may help some adults with metastatic colorectal cancer become eligible for surgery.
Updated on Oct. 23, 2026 in Cancer
Live Poll
Do you believe new immunotherapy treatments for advanced cancers provide enough benefit to justify the investment?
Initial findings from a Phase Ia clinical trial show that the experimental immunotherapy STC-1010 may help shrink advanced, hard-to-treat colorectal tumors. The early results offer a potential new pathway for patients with metastatic disease to regain eligibility for surgical removal of their tumors.
Why it matters
Most metastatic colorectal cancers are resistant to current immunotherapies, leaving patients with limited options once chemotherapy fails. This development is significant because it aims to make these invisible tumors recognizable to the body's immune system, potentially shifting treatment possibilities for those with advanced disease.
This Phase Ia trial evaluated 9 patients with advanced colorectal cancer, finding an objective response rate of 57% among the 7 evaluable participants. While these preliminary findings suggest potential, the study is small and ongoing.
The players
Brenus Pharma
A biotechnology company focused on developing STC-1010, an immunotherapy platform designed to make tumors visible to the immune system.
Centre Georges-François Leclerc
A research center located in Dijon that specializes in clinical oncology and the development of new cancer therapies.
The details
STC-1010 uses a proprietary platform designed to mimic tumor protein expression, effectively training the immune system to recognize and attack pMMR/MSS tumors that typically evade detection. Patients received the treatment in combination with low-dose oral cyclophosphamide and chemotherapy, which helps prime the immune response. Data showed a 285% increase in CD8+ T-cell infiltration and up to a 97% reduction in circulating tumor DNA, indicating the drug may successfully stimulate an active anti-tumor defense.
Timeline
The data cut-off for the clinical study was June 8, 2026.
Brenus Pharma announced the Phase Ia study results on October 23, 2026.
Health Landscape
Approximately 95% of metastatic colorectal cancers are classified as pMMR/MSS, a group historically unresponsive to traditional immunotherapy. This research represents an effort to expand the scope of treatable cancers by engineering biological markers that force tumors to become visible to the immune system.
These findings are preliminary and currently limited to a small clinical study, meaning they are not yet an available treatment option for the public. Patients managing advanced colorectal cancer should discuss their eligibility for clinical trials with their oncologist to track ongoing research developments.
The takeaway
The study suggests that priming the immune system with STC-1010 could potentially help reduce tumor burden in patients previously considered untreatable. If you or a loved one are exploring new treatment avenues, ask an oncologist whether your tumor's specific molecular profile makes you a candidate for ongoing clinical trials.
Further reading
For more information on current treatment pathways, explore our comprehensive guide on Cancer.
More information
View the complete findings in the official company press release.
Source note: This article includes information reported by Iberonews.
Live Poll
Do you believe new immunotherapy treatments for advanced cancers provide enough benefit to justify the investment?
